Table 3.
Baseline demographics and PRO scores for the subgroup of patients previously treated with first-line injectable therapies (glatiramer acetate, all forms of interferon beta)
| Parametera | Baseline score | Number |
|---|---|---|
| Age, years | 46.8 (10.4) | 123 |
| Females, n (%) | 77 (62.6) | 123 |
| EDSS score | 2.4 (1.7) | 116 |
| Time since diagnosis, years | 9.77 (6.08) | 123 |
| MSIS total score | 49.3 (17.8) | 122 |
| Number of relapses in 2 years prior to Visit 1 | 0.65 (0.77) | 123 |
| TSQM convenience score | 84.3 (14.1) | 120 |
| TSQM effectiveness score | 66.6 (15.1) | 120 |
| TSQM global satisfaction score | 64.1 (15.4) | 119 |
| TSQM side effects score | 92.9 (16.6) | 120 |
EDSS Expanded Disability Status Scale, MSIS Multiple Sclerosis Impact Scale, SD standard deviation, TSQM Treatment Satisfaction Questionnaire for Medication
aMean (SD) unless otherwise noted